Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.35 |
| ▸ | ITGAV | P06756 | 5/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415220 | 0.95 | ITGB1 (0.36) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7422540 | 0.91 | ITGB3 (0.42) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7408422 | 0.90 | ITGB1 (0.40) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| Trifluoroacetic Acid SCHEMBL7415325 | 0.90 | ITGB3 (0.44) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7415327 | 0.88 | ITGB1 (0.42) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7416602 | 0.88 | ITGB3 (0.38) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7417563 | 0.88 | ITGB3 (0.39) | ITGB3ITGA2BITGAV | |
| SCHEMBL7408394 | 0.88 | ITGB3 (0.37) | ITGB3ITGA2BITGB1ITGA5PPARA | |
| SCHEMBL7412118 | 0.88 | ACLY (0.38) | ITGB3ITGA2BITGB1ITGA5PPARA | |
| SCHEMBL7416087 | 0.88 | POLB (0.37) | ITGB3ITGA2BITGAVITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |